16 September 2026 editorial review · Item
Inreda AP (dual-hormone): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Inreda AP (dual-hormone)
Scope and findings:
- Read published PANORAMA abstract: 34 randomized,20 primary-analysis completers, TIR 81/57, TBR0.9/1.2 with CI crossing zero. Added separate-population caveat. Current manufacturer supports CE AP5/project-only access, AP6 development, daily glucagon refill; removed unsupported single-insurer certainty.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.